TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00074490
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
Study: NCT00074490
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
Study: NCT03841201
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT03841201
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: iv infusion
Study: NCT03566485
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT03566485
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by mouth
Study: NCT03566485
Drug: Idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT03646396
Drug: Sofosbuvir-daclatasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-daclatasvir for 3 months
Study: NCT00067002
Drug: Rituxan
Normalized name: Rituxan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
Study: NCT00067002
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m2 by vein on Day -8.
Study: NCT00067002
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/Kg by vein on Day -7.
Study: NCT01133912
Drug: paclitaxel, gemcitabine, lapatinib
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
Study: NCT00067002
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 by vein on Days -6 to -3.
Study: NCT00067002
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
Study: NCT01010646
Drug: IFN alfa-2b XL 27 MUI + Ribavirin
Normalized name: Interferon Alfa-2B
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
Study: NCT01010646
Drug: IFN alfa-2b XL 36 MUI + Ribavirin
Normalized name: Interferon Alfa-2B
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
Study: NCT01010646
Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
Study: NCT02056587
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
Study: NCT03780166
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib administered orally once daily at the cohort-specified dose level.
Study: NCT01140126
Drug: Antibody UB-421
Normalized name: UB-612
DrugBank: UB-612 (DB16444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
Study: NCT00717808
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
Study: NCT00722306
Drug: PD 0200390
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
Study: NCT00030914
Drug: medroxyprogesterone
Normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030914
Drug: venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01481818
Drug: EGCG
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
Study: NCT00002630
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02781259
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
Study: NCT03614156
Drug: Rapastinel
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
Study: NCT03980704
Drug: IMPACT
Normalized name: Impact
DrugBank: Topramezone (DB14826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral immunostimulating oral supplement
Study: NCT02407600
Drug: FOSAPREPITANT (Emend)
Normalized name: fosaprepitant Injection [Emend Injection]
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
Study: NCT03650764
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
Study: NCT03650764
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is commercially available
Study: NCT03070964
Drug: plitidepsin
Normalized name: plitidepsin
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587924
Drug: rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT03172416
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
Study: NCT03172416
Drug: Oxaliplatin & Nivolumab
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
Study: NCT01915069
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03586466
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
Study: NCT01106248
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Study: NCT01286051
Drug: Follistim plus Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follistim plus single injection of ganirelix
Study: NCT01707199
Drug: Artesunate + Sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.
Study: NCT02447302
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03869697
Drug: SCB-313
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 20 mg lyophilized powder in a single-use glass vial
Study: NCT00002618
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002618
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002618
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02165098
Drug: Cariprazine prolonged release tablet A
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine prolonged release tablet A - fasted
Study: NCT02165098
Drug: Cariprazine prolonged release tablet B
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine prolonged release tablet B - fasted
Study: NCT02165098
Drug: Cariprazine capsule
Normalized name: cariprazine Oral Capsule
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine capsule - fasted
Study: NCT02165098
Drug: Cariprazine PR tablet A
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine Prolonged Release tablet A - fed
Study: NCT02165098
Drug: Cariprazine PR tablet B
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine Prolonged Release tablet B - fed
Study: NCT01439828
Drug: N-acetylcystein
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
Study: NCT00314795
Drug: Peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginesatide injection
Study: NCT01010867
Drug: Lactobacillus plantarum strains 299 and 299v
Normalized name: LACTOBACILLUS PLANTARUM 299
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a daily dose of Lactobacillus plantarum: 1 x10\^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)
Study: NCT02052999
Drug: PAC-14028 cream 1%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
Study: NCT02452008
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
Study: NCT03200080
Drug: Tozadenant
Normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2, 4, 6 or 8 Tozadenant 60 mg tablets
Study: NCT03200080
Drug: d-amphetamine
Normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
Study: NCT00026169
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT00000921
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00909298
Drug: TTP889
Normalized name: TTP889
DrugBank: TTP889 (DB05131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg
Study: NCT00348348
Drug: Besifloxacin
Normalized name: Besifloxacin
DrugBank: Besifloxacin (DB06771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
Study: NCT00348348
Drug: Moxifloxacin solution
Normalized name: moxifloxacin Ophthalmic Solution
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
Study: NCT03699215
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
Study: NCT03433040
Drug: 17-Hydroxyprogesterone Capronate
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg
Study: NCT00249899
Drug: Lapaquistat acetate and stable statin therapy
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Study: NCT02352831
Drug: Tosedostat
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03195946
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets for oral use, 10 mg/day
Study: NCT03195946
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: syrup for oral use, 4mg/day
Study: NCT03195946
Drug: Cocktail of CYP450 substrates
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
Study: NCT00742404
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00742404
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02329834
Drug: Fursemide Injection Solution for subcutaneous administration (80 mg)
Normalized name: furosemide Injectable Solution
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
Study: NCT02329834
Drug: Furosemide Injection, USP
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
Study: NCT02475109
Drug: PAN-90806 Ophthalmic Solution
Normalized name: calcium carbonate
DrugBank: AN-9 (DB05103)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00660153
Drug: Tivozanib (AV-951) plus FOLFOX6
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15.
Study: NCT05371262
Drug: Levothyroxin
Normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
Study: NCT00401414
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg tablets take as directed by study staff (based on INR)
Study: NCT03959176
Drug: Brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 drops administered once in the left eye in both study arms
Study: NCT03959176
Drug: Tropicamide
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop administered at two different times points in both eyes in both study arms
Study: NCT03959176
Drug: Phenylephrine Ophthalmic Product
Normalized name: phenylephrine Ophthalmic Product
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop administered at two different time points in both eyes in both study arms
Study: NCT05188833
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
Study: NCT02109185
Drug: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03240549
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
Study: NCT00089401
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02722083
Drug: Chlorpheniramine maleate (BAY X002134)
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tablet, single dose, orally
Study: NCT03515668
Drug: Ritalin 20 mg Tablet
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose for all participants
Study: NCT00644800
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
Study: NCT03944317
Drug: Sulfadoxine pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
Study: NCT00006206
Drug: naltrexone (Revia)
Normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006206
Drug: acamprosate (Campral)
Normalized name: acamprosate calcium Delayed Release Oral Tablet [Campral]
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00842751
Drug: First Intervention (7 days)
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
Study: NCT00842751
Drug: Second Intervention (7 days)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
Study: NCT00842751
Drug: Third Intervention (7 days)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
Study: NCT01376804
Drug: valganciclovir [Valcyte]
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, daily for up to 200 days.
Study: NCT00420771
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
Study: NCT00785642
Drug: Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
DrugBank: Tangerine (DB10637)
Approvals — FDA: no, EMA: no, PMDA: no